KdT Ventures has signed off on a $608 million biobucks dea l for NGM Biopharmaceuticals’ phase 2-ready metabolic-dysfunction ...

Back-to-back clinical failures have dealt further blows to efforts to treat Parkinson’s disease by targeting alpha-synuclein.

Astellas is continuing to strengthen its neurological disease gene therapy capabilities, handing Sangamo Therapeutics $20 ...

Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the ...

After its rare disease drug was rejected by the FDA in late November, Applied Therapeutics vowed to fight on with a ...

Two months after former Seagen CEO David Epstein unveiled his new project, the biotech has secured "over" $140 million in ...

Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...

As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and ...

Flagship CEO-partner and Ring CEO Tuyen Ong, M.D., will also be shifting to an advisory role in the new year, according to ...

Italian VC XGEN Venture has closed a 180 million euro ($190 million) fund for biotech and medtech companies. | Italian VC ...

Alphabet spinoff SandboxAQ has raised more than $300 million to go toward developing AI applications across multiple areas ...

Freshly public BioAge Labs has secured a multiyear partnership with Novartis that focuses on age-related diseases and ...